AI model could match kidney cancer patients to better treatments
NCT ID NCT07332923
First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study looks at 500 people with clear cell kidney cancer. Researchers will use CT scans and machine learning to predict levels of a protein called HIF-2α, which helps decide if a targeted drug (Belzutifan) might work. The goal is to match the right treatment to the right patient, avoiding unnecessary side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOMICS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
first hospital affiliated of Fujian medical university
Fuzhou, Fujian, 350005, China
Conditions
Explore the condition pages connected to this study.